Preferred Label : Protease-activated Anti-EGFR/Anti-CD3 Bispecific Antibody Prodrug CX-904;
NCIt synonyms : TCB Antibody CX-904; Anti-EGFR/Anti-CD3 T-cell Engaging Bispecific Probody AMG 651; EGFR x CD3 Bispecific Antibody Prodrug CX-904; Anti-EGFR/Anti-CD3 Bispecific Probody AMG 651; Anti-EGFR/Anti-CD3 T-cell Engaging Bispecific Probody CX-904; T-cell-engaging Bispecific Antibody CX-904; Anti-EGFR/CD3 Bispecific Antibody Prodrug CX-904; Anti-EGFR/Anti-CD3 Bispecific Probody CX-904;
NCIt definition : A recombinant bispecific antibody prodrug composed of a bispecific antibody directed
against the tumor-associated antigen (TAA) human epidermal growth factor receptor
(EGFR; HER1; ErbB1) and the human T-cell surface antigen CD3 that is linked to a proprietary
masking peptide through a protease-cleavable linker, with potential immunostimulating
and antineoplastic activities. Upon administration of protease-activated anti-EGFR/anti-CD3
bispecific antibody prodrug CX-904, the linkage system is stable in the circulation
and, upon extravasation into the tumor microenvironment (TME), the peptide mask is
cleaved by tumor-associated proteases. These proteases are present in high concentrations
and aberrantly activated in the TME, while expressed as inactive forms, at much lower
concentrations, in normal, healthy tissue. Protease cleavage of the linker enables
binding of the unmasked, fully active bispecific antibody moiety of CX-904 to both
CD3 on cytotoxic T-lymphocytes (CTLs) and EGFR on EGFR-expressing tumor cells. This
activates and redirects CTLs to EGFR-expressing tumor cells, leading to CTL-mediated
killing of EGFR-expressing tumor cells. EGFR, upregulated and/or mutated in a variety
of tumor cell types, plays a key role in tumor cell proliferation and survival.;
Molecule name : AMG-651; CX-904; CX 904; AMG 651;
NCI Metathesaurus CUI : CL1792834;
Origin ID : C188057;
UMLS CUI : C5706450;
Semantic type(s)
- chemical_or_drug_has_mechanism_of_action
- concept_is_in_subset
- has_target
